Chromodomain-helicase-DNA-binding protein 7 (CHD7)

Chromodomain-helicase-DNA-binding protein 7 (CHD7) is an ATP-dependent chromatin remodeling enzyme belonging to the CHD family, which plays a critical role in regulating chromatin accessibility and epigenomic states at enhancers and promoters[1][2][3]. CHD7 contains chromodomains, a Snf2-like helicase-ATPase domain, and SANT-SLIDE domains, enabling it to recognize histone modifications (such as H3K4me1) and to reposition or slide nucleosomes to regulate gene expression[2][3]. Mutations or haploinsufficiency of CHD7 cause CHARGE syndrome, a severe developmental disorder affecting multiple organ systems, especially the nervous system and cerebellar morphogenesis[1][2]. CHD7 functions primarily by maintaining open, transcriptionally active chromatin at regulatory DNA elements, controlling gene programs essential for tissue and brain development[1][3]. There are currently no known drugs that specifically target CHD7, but its dysfunction is implicated primarily through genetic disruption[2][3].

Other names

CHD7KIAA1416CHD-7FLJ20357FLJ20361ATP-dependent helicase CHD7CRGHH5IS3KAL5CHARGE association

Drugs targeting CHD7 (if available) would likely inhibit or modulate its ATP-dependent chromatin remodeling activity, altering gene expression at specific loci.